🎉 We're thrilled to announce that Therapeutic Advances in Gastroenterology (@TAGastroenterol) has reached 1,000+ followers! 🚀 Thank you for being part of our journey to advance clinical gastroenterology research. Here's to many more milestones! #Gastroenterology

🔎 IBD is linked to hepatobiliary & pancreatic diseases, with strongest evidence for increased gallstone (OR=1.72) & acute pancreatitis (OR=3.11) risk. Liver cancer & portal vein thrombosis also showed highly suggestive associations. 📖 Read more:

📢 Thrombocytopenia may not increase the risk of endoscopic variceal treatment (EVT) failure in cirrhotic patients with acute variceal bleeding (AVB). Findings from a multicenter study challenge prior concerns over low platelet counts. 🔗 Read more:

Partial cystectomy may be a viable surgical option for colorectal cancer (CRC) patients with pathological bladder invasion, offering similar survival rates to total cystectomy. Study findings challenge standard practice. 🔗 Read more:

Mirtazapine significantly improved functional dyspepsia symptoms in an 8-week randomized clinical trial. Patients saw reduced nausea, early satiation & postprandial fullness, with better QoL vs. control. Could this be a new FD treatment option? 🔗

@Muni_Kurtz This is part of our Special Collection with Takeda on IBD advances! Stay tuned for more cutting-edge research in treatment sequencing, drug optimization & imaging. 📚 Explore the collection:

🔬 Poor sleep is common in IBD—and it's not just a symptom. This long-term study found that poor sleep quality is independently linked to active disease and lower quality of life, reinforcing the need to address sleep in IBD care Read more: #SleepHealth

This study is part of our Special Collection on Inflammatory GI Disorders Unveiled: Mechanisms and Emerging Treatments—exploring novel diagnostics, therapies, and management strategies for Crohn’s, UC, diverticular disease, and more. Submit your research: 

Dual-targeted therapy combining biologics & small molecules shows promise for refractory #IBD, with 57.4% achieving remission & 51.7% showing endoscopic response in a multicenter study. Safety profile was manageable, with 2.1% serious AEs. Full study:

New review examines the effectiveness and safety of dual biologic therapy in #IBD, exploring its potential to improve treatment for #CrohnsDisease and #UlcerativeColitis. Findings suggest combination approaches could reshape management strategies Read:

This research is part of the Women's Research In: Therapeutic Advances in Gastroenterology Special Collection, highlighting impactful contributions by women in the field. Learn more:

New research tracks gastrointestinal bleeding (GIB)-related deaths in the U.S. from 2010 to 2023. During COVID-19, GIB mortality surged—peaking in 2021—especially in young males (19–44 years). Rates stabilized by 2023 Full study:

A prospective trial compared 10-day vonoprazan–amoxicillin (VA) dual therapy to 14-day esomeprazole–amoxicillin (EA) for H. pylori eradication. The 10-day VA regimen showed higher eradication rates (91.1% vs 85.5%, PP analysis) and better compliance.

Thanks to Dr. Kristle Lynch (@KristleLynchMD), Dr. Gary Falk (@DrGaryFalk), and the team for their valuable work on EGJOO and improving diagnostic accuracy!

Early Ustekinumab intervention within 6 months of Crohn’s disease diagnosis was linked to higher clinical and endoscopic remission rates, along with fewer complications. These findings highlight the importance of early UST in CD management Read more:

A study of 8,796 individuals who underwent colonoscopy suggests that higher food-specific serum IgG reactivity (FSsIgGR) is linked to a reduced risk of colorectal adenomas (CAs), with BMI mediating 6% of the effect. Explore the full analysis:

A post hoc analysis shows that patients with eosinophilic esophagitis continuing Budesonide oral suspension had lower relapse rates (28% vs 60.9%) than those switched to placebo. BOS maintained efficacy across histologic, symptom, & endoscopic endpoints 🔗